7.12 Smoking and mental health

Last updated: March 2018      Suggested citation: Greenhalgh, EM., Stillman, S., & Ford, C. 7.12 Smoking and mental health. In Scollo, MM and Winstanley, MH [editors]. Tobacco in Australia: Facts and issues. Melbourne: Cancer Council Victoria; 2018. Available from http://www.tobaccoinaustralia.org.au/chapter-7-cessation/7-12-smoking-and-mental-health

7.12.0 Introduction

In Australia, while the prevalence of smoking is declining in the general community, it remains high among people with mental illness.¹ Compared with the general population, people with mental illness have higher smoking rates, higher levels of nicotine dependence, and a disproportionate health and financial burden from smoking.^{2, 3} Smokers with co-occurring mental illness or substance use disorders have limited access to cessation treatment, longer durations of smoking, and lower rates of quitting. Such smokers are also far more likely to die from their smoking than as a result of their psychiatric condition.² Australian men with mental illness live 15.9 years less and women live 12 years less than those without mental illness,⁴ and most of the excess morbidity and mortality is attributable to smoking-related illnesses such as cardiovascular disease, respiratory disease, and cancer.^4, 5

The mechanisms underlying the relationship between mental health conditions and smoking are complex, and vary between disorders.⁶ Smokers often perceive their smoking to be helpful in relieving or managing psychiatric symptoms, such as feelings of depression, anxiety, and stress.⁷ Many mental health workers also believe that smoking cessation will exacerbate mental illness.⁸ However, recent evidence suggests that the reverse is true; quitting smoking for at least six weeks actually improves mental health, mood, and quality of life, both among the general population and among people with a psychiatric disorder.⁷

Smokers with mental illness are as motivated to quit as the general population, and despite lower overall success rates, can quit successfully.⁹ Integrating tobacco cessation interventions into routine mental health treatment, and providing more intensive intervention when required, forms an important part of reducing the large health disparities between those with and without a mental health problem.^{6, 7}

This section includes information on:

• 7.12.1 Prevalence of smoking among people with mental health problems
• 7.12.2 Smoking prevalence over time among those with mental health problems
• 7.12.3 Why those with mental health problems are more likely to smoke
• 7.12.4 Barriers to be overcome when quitting
• 7.12.5 Interventions for reducing smoking for those with a mental health problem
  
  • 7.12.5.1 Depression
  • 7.12.5.2 Anxiety
  • 7.12.5.3 Attention-deficit/hyperactivity disorder (ADHD)
  • 7.12.5.4 Substance use disorders
  • 7.12.5.5 Post-traumatic stress disorder (PTSD)
  • 7.12.5.6 Bipolar disorder
  • 7.12.5.7 Schizophrenia
• 7.12.6 The role of health professionals and health settings

7.12.1 Prevalence of smoking among people with mental health problems

Data from the National Drug Strategy Household Survey show that in Australia in 2016, daily smokers were more than twice as likely to have high/very high levels of psychological distress compared with people who had never smoked (22% compared with 10%, respectively) and were more than twice as likely to have been diagnosed or treated for a mental health condition (29% compared with 12%).¹⁰ Smoking prevalence tends to increase alongside the severity of the psychiatric disorder.⁸ For example, two Australian studies conducted 10 years apart both found that among people living with psychotic disorders, about 70% of men and 60% of women are smokers.^1, 11 Figure 7.12.1 shows the prevalence of smoking among people diagnosed and/or treated for mental disorders in Australia in 2016.

Results from the 2014–15 National Health Survey show a similarly high prevalence of smoking among people with mental disorders, and also show the extremely high prevalence of smoking among those with harmful use or dependence on alcohol or drugs.

International data also show high smoking rates among those with mental illness. Large-scale survey research has found that those with any current psychiatric diagnosis had more than three times greater odds of currently smoking than those with no diagnosis, and were much less likely to quit.¹⁵ Among people with anxiety disorders, smoking rates appear to range from 31.5% for people with social phobia to 54.6% for people with generalised anxiety disorder.¹⁶ Smoking rates are also disproportionately high among people with depression, and conversely, smokers have significantly higher rates of lifetime depression.⁶ Another study in the US found that adults with serious psychological distress were more likely to be current smokers and to smoke heavily, and less likely to quit than those without serious psychological distress.¹⁷ US studies^{18, 19} have estimated that while nicotine-dependent individuals with a comorbid psychiatric disorder make up only 7.1% of the population, they consume more than one-third of all cigarettes.

A 2014 survey of secure mental health services in the UK found that 64% of mental health patients were smokers, compared with 18% of the general population.²⁰ A meta-analysis of studies from 20 different countries found that people with schizophrenia have more than five times the odds of current smoking than the general population, and smoking cessation rates are much lower in smokers with schizophrenia compared with the general population.²¹ Research in the US and Europe has consistently found that the prevalence of smoking is approximately two to three times higher among people with bipolar disorder than in the general population.⁶ Limited data suggest that smoking appears highly prevalent among adolescents with diagnoses of mental illness.²² Both adults and adolescents with ADHD smoke at significantly higher rates than the general population,⁵ and the risk of smoking increases with the number of symptoms.²³

An Australian study of people with psychotic illness found that current smokers smoked on average 21 cigarettes per day,¹ compared with an average of 14 cigarettes per day among smokers in the general Australian population.²⁴ Among smokers with severe mental illness, other studies indicate average daily consumption of 30 cigarettes, with a range of 5–80 per day.^25,26 Smokers with schizophrenia smoke more heavily and are more nicotine dependent,²⁷ and extract more nicotine from each cigarette.²⁸ Evidence suggests that major depression may be a risk factor for progression of nicotine dependence.²⁹

7.12.2 Smoking prevalence over time among those with mental health problems

In Australia, while the prevalence of smoking is declining in the general community, it remains high among people with mental illness. For example, the prevalence of smoking among Australians with psychotic disorders remained steady at about 67% between 1997 and 2010, while smoking in the mainstream Australian population declined from 26% to 19%.¹ The gap in life expectancy between those with and without mental illness has also widened over time, largely due to smoking-related diseases.⁴ Similarly in the US, several studies have shown growing disparities over time between smoking in the general population and among people with high levels of psychological distress and serious mental illness.^30-33 As overall smoking rates decline, those with serious psychological distress comprise a greater proportion of the remaining smokers.³⁴ These findings suggest that tobacco control policies and cessation interventions that have effectively reduced smoking in the general population have not been as effective for people with severe mental illness.

Nonetheless, there are some encouraging trends. Several US studies have shown increased quit rates over time among people with psychological distress and some mental disorders.^{35, 36} Data from the two most recent ABS Health Surveys show that daily smoking prevalence among those with non-psychotic disorders appears to have declined in line with the general population.

7.12.3 Why those with mental health problems are more likely to smoke

There are a number of potential explanations for why people with mental health problems are more likely to smoke; risk factors for smoking among the general population are experienced to a greater degree, and there are also unique factors that contribute to the higher prevalence of smoking. These include:

• the historical and environmental context: many mental health institutions have a strong smoking culture and have traditionally condoned and encouraged smoking, with cigarettes used by staff to build rapport, calm, reward, or punish clients.^38-41 Mental health staff may also hold negative attitudes toward patients quitting.⁴²
• self-medication, such that smoking is perceived to have a beneficial effect on cognition and mood, and to relieve symptoms of mental illness such as anxiety and stress.⁴³
• the psychosocial disadvantage of many people living with mental illness,⁴⁴ including lower-than-average education levels and income,³⁸ and high levels of unemployment.⁴⁵
• social inclusion, such that smoking can be perceived as a way to fit in, cope with exclusion, and alleviate stigma among people with severe mental illness.⁴⁶
• a shared genetic predisposition to smoking and mental illness.⁴³

The self-medication hypothesis suggests that people with mental illness smoke to ease the symptoms of depression, schizophrenia, substance abuse and other disorders, and is the most common explanation for the very high prevalence of smoking among this group.^38, 47 The hypothesis has also been expanded to suggest that smoking can relieve side effects of antipsychotic medication.⁴¹ Smokers with mental illness frequently cite stress and anxiety relief as reasons for smoking,⁴⁵ and young people with mental illness perceive nicotine as protective against the adverse effects of stressful stimuli.²² However, results from recent studies have led to questioning of the self-medication hypothesis^{48, 49} (with the exception of ADHD—see Section 7.12.5.3). The supposed beneficial effects of smoking on stress can be largely attributed to the temporary alleviation of nicotine withdrawal symptoms, which creates the false impression that smoking is relaxing.⁵⁰ However, smoking actually increases stress levels overall.⁸ A 2014 meta-analysis found that quitting for at least six weeks is associated with reduced depression, anxiety, and stress and improved positive mood and quality of life compared with continuing to smoke among people with psychiatric disorders.⁷ Smoking is also associated with suicidal ideation, suicide plan, suicide attempt, and suicide death,⁵¹ but this association is reduced when a person quits.⁵² Among people with psychosis, one study estimated that smoking contributed to 21% of suicidal behaviours;⁵³ reducing consumption may also reduce suicidality in this population.⁵⁴  A review of smoking among people with schizophrenia concluded that, despite some enhanced performance for cognitive tasks, smoking appears to be less beneficial on schizophrenic symptomology than generally assumed, while clearly increasing the risk of cancer and other smoking-related diseases responsible for early mortality.⁴⁸ A 2015 systematic review and meta-analysis also concluded that daily tobacco use is associated with increased risk of psychosis and an earlier age at onset of psychotic illness. The authors propose that smoking could have a causal role in psychosis, which further brings into question the self-medication hypothesis.⁵⁵ Smoking may also increase the risk of anxiety and depression.⁸

Another proposed explanation for the higher rates of smoking among people with mental health problems is that once addicted, they find it much more difficult to quit than the general population. Although treating tobacco dependence in people with mental illness is challenging, several randomised treatment trials and systematic reviews have documented that success is possible.⁵⁶ Smokers with chronic mental illness are able to quit with standard cessation approaches with minimal effects on psychiatric symptoms.⁵⁷ (See Section 7.12.5) Socio-economic status (SES) is inversely related to smoking, such that the prevalence of smoking is substantially higher among lower socio-economic groups (see Chapter 1.7). Mental disorders are associated with low incomes and higher levels of debt;⁵⁸ thus, there is likely interplay between low socioeconomic status, mental illness, and smoking. In 2011–12, 62% of working age Australians with a mental illness were employed, compared to 80% of those without a mental illness.⁵⁹ One study found that smokers with mental illness frequently smoke to combat boredom, and suggested that the higher rates of unemployment among this group may contribute to more frequent experiences of boredom and therefore smoking.⁴⁵ (See Section 7.19.2 and Chapter 9, Section 9.6.4)

Looking at why and how some people resist smoking despite being at-risk can also shed light on potential protective factors.⁶⁰ One small study with people diagnosed with mental illness found that strong, negative attitudes to smoking as children that have persisted into adulthood, lasting associations with smoking, a clear sense of ‘self’ separate from peers from an early age, and developing a range of coping strategies and external supports not related to smoking served as protective factors from taking up smoking.⁶⁰

7.12.4 Barriers to be overcome when quitting

People with mental health problems face a number of unique barriers to quitting, including misperceptions regarding the safety of stopping smoking, higher levels of nicotine dependence and withdrawal, lower degree of participation in programs, misperceptions of low motivation to quit, socio-economic factors, and systematic barriers to quitting in mental healthcare settings. A systematic review identified smoking for stress management, lack of support from health and other service providers, the high prevalence and acceptability of smoking in vulnerable communities, and the maintenance of mental health as perceived barriers among those with mental illness.⁶¹ An Australian study of smoking behaviours among institutionalised psychiatric populations found systematic barriers to quitting, including cigarettes being the currency by which economic, social and political exchange took place and complex processes of reinforcement to smoke. Escape from the smoking culture of the settings appeared to be extremely difficult for clients and staff.⁶²

There is a common false belief within mental health settings that quitting smoking interferes with recovery from mental illness, eliminates a coping strategy, and leads to decompensation in mental health functioning.⁵⁶ People with mental illness also report similar concerns, which can hinder quit attempts.⁶³ However, several major reviews have found that quitting does not lead to deterioration in symptoms of schizophrenia, depression, or severe mental illness,^{64, 65} and is in fact associated with improvements in mental health among people with psychiatric disorders.⁷ Smoking cessation also does not exacerbate anxiety or PTSD symptoms, or lead to psychiatric hospitalisation or increased use of alcohol or illicit drugs.^{39, 66} Indeed, smoking cessation interventions during addictions treatment appear to enhance rather than compromise long-term sobriety.⁶⁷ Two studies examining whether the treatment of ADHD can enhance response to smoking cessation intervention found no association overall between abstinence and change in ADHD symptoms,^{68, 69} and another found that quitting can reduce anxiety and depressed mood in smokers with ADHD.⁷⁰ Quitting is also associated with a decreased likelihood of suicide attempt.⁵² Lifetime history of major depression does not appear to be an independent risk factor for failure in smoking cessation treatment.⁷¹

Another common misperception is that people with mental illness do not want to quit, which can lead to a lack of encouragement and support to do so.⁷² A study of mental health centres found that the most common barrier to staff implementing smoking cessation treatment was a perceived lack of patient interest in quitting.⁷³ Although the co-presence of mental illness can make quit attempts more challenging⁷⁴ and less successful,⁷⁵ smokers with mental health disorders are motivated to quit.⁹ Studies involving patients recruited from outpatient and inpatient psychiatric settings suggest that they are just as likely as the general population to want to quit smoking.³⁹ Further, contrary to common beliefs, greater psychiatric symptoms have been shown to predict greater, not lesser, motivation to quit smoking.⁷⁶ In British surveys, about half of smokers with mental illness have expressed an interest in quitting when asked.⁷⁷ In the US, 20–25% of smokers with mental illness report that they intend to quit smoking in the next 30 days, and another 40% say they intend to do so in the next six months.⁵⁶  Another population-level study in the US found that smokers with mental illness were more likely than those without mental illness to attempt quitting, and just as likely to use cessation treatment.⁷⁸ Inpatients with mental health disorders appear to be no less motivated to stop smoking than those without mental health disorders and their use of NRT during hospitalisation is similar.⁷⁹ One Victorian study of consumers at a psychiatric disability rehabilitation and support service found that while smoking rates were almost four times higher than the general population, there was high interest in quitting and cutting down.⁸⁰ US research found that, among a sample of women with PTSD symptomatology and serious mental illness, readiness and intention to quit smoking was high.⁸¹ Smokers with mental illness cite similar reasons for wanting to quit as the general population. For example, one study found that health concerns (73%), cost (71%), advice from a doctor (54%), and advice from others (64%) prompted a desire to quit, while social support from family and friends (58%), direction from a doctor (46%), use of NRT (31%), and the advice of friend who had quit (23%) were factors that enabled quitting.⁸²

7.12.5 Interventions for reducing smoking for those with a mental health problem

Smoking has a disproportionate impact on the mental and physical health of people with mental illness, therefore treating nicotine dependence should be a high priority and form part of routine care.⁸ However, progress in the development of cessation treatments for people with mental health problems has traditionally been slow, in part because smokers with a current mental disorder have been excluded from most smoking cessation trials.⁸³ Given the growing body of evidence showing that quitting is typically not detrimental to psychiatric symptoms and, in fact, may lead to improvements in mental health and wellbeing,^7, 84 cessation should be encouraged and supported among smokers with comorbid mental disorders as it is among smokers in the general population.⁶ However, as with any other stressor, the stress of cessation could temporarily affect symptoms;³⁹ therefore, monitoring of patients’ psychiatric status during the quitting process is warranted.⁶ Nonetheless, people with a mental illness should be offered the same smoking cessation interventions that have been shown to be effective in the general population,⁸⁵ with optimal treatment comprising behavioural and pharmacotherapy interventions, alone or in combination.⁸⁶ Smokers with chronic mental illness can successfully quit with standard cessation approaches, and longer maintenance on pharmacotherapy can reduce the typically high rates of relapse without detrimental effects on psychiatric symptoms.⁵⁷

An important consideration in treating nicotine dependence is the impact of smoking on psychiatric treatment. Smoking complicates the treatment and course of psychiatric disorders through its profound effect on the metabolism of pharmacotherapies, and is therefore one of the factors that leads to individual differences in drug responses.⁶ For example, smoking can interfere with the medications taken for schizophrenia and depression, therefore the doses of some psychotropic medications may need to be decreased following cessation.^{85, 87} Patients with mental illness can be offered the same cessation medications as the general population,⁸⁸  but should be monitored closely. The typically higher levels of nicotine dependence among smokers with mental illness mean that larger doses of NRT, combination pharmacotherapy, and a longer duration of therapy may be necessary.⁸  Australian research found that cessation support after discharge from an inpatient psychiatric facility was effective in encouraging quit attempts and reducing cigarette consumption up to 6 months post-discharge.⁸⁹

SANE Victoria and Quit SA, in collaboration with the Tobacco and Mental Illness project in South Australia, have each developed resources to help long-term psychiatric clients to quit, and resources for carers and mental health workers to use as well as a group program for smoking cessation.^90,91 Similar programs have been run in other states.⁹² All state and territory Quitline services adhere to protocols for tailoring assistance to callers with mental illness. As well as training Quitline counsellors in the special issues for people with mental illness, they co-ordinate intervention with the person’s healthcare professionals.⁹³

7.12.5.1 Depression

Compared to people without depression, people with depression are about twice as likely to be smokers, and are less likely to succeed in quit attempts.^{94, 95} They are also more nicotine dependent, more likely to suffer from negative mood changes after nicotine withdrawal, more likely to relapse, and experience disproportionate morbidity and mortality from smoking-related disease.⁹⁴ Depression is also related to psychosocial characteristics that make it more difficult to stop smoking, for example, lower self-esteem and self-efficacy for quitting, and greater likelihood of unemployment, poorer social support networks and poorer physical health.⁹⁶ Recent findings from the Four Country (Canada, US, UK, and Australia) International Tobacco Control Study showed that smokers with depressive symptoms or diagnosis make more quit attempts than people without depression, but they were also more likely to relapse in the first month.⁹⁷ Despite this, meta-analyses suggest that a lifetime history of major depressive disorder, in itself, does not predict failure to quit smoking.⁷¹  A 2015 review of depression and smoking concluded that: depressed smokers are motivated to quit; smoking cessation does not exacerbate symptoms of depression; depression does not have a negative impact on smoking cessation outcomes; and the self-medication hypothesis does not account for tobacco dependence and depression co-morbidity.⁹⁸ Indeed, a growing body of evidence supports the beneficial role of quitting in reducing depression.^7, 99

A meta-analysis of treatment trials in smokers with depression published in 2010 concluded that NRT was more effective than placebo, and that adding behavioural mood management to cessation counselling improved treatment outcomes. Notably, only three trials included smokers with current depression, therefore the findings were most relevant to smokers with a history of depression.¹⁰⁰ A 2013 Cochrane review evaluated the effectiveness of smoking cessation interventions in smokers with current or past depression. It concluded that adding a psychosocial mood management component to a standard smoking cessation intervention increases long-term cessation rates in smokers with both current and past depression when compared with the standard intervention alone. Bupropion was beneficial for smokers with a history of depression, but there was a lack of evidence regarding its use with smokers with current depression. There was not enough evidence regarding the effectiveness of other antidepressants for quitting in current or past depression, nor for the effectiveness of standard smoking treatments that do not target depression, such as nicotine replacement therapy and psychosocial smoking cessation interventions.⁹⁴  A placebo controlled trial published in 2013 examined the effects of varenicline on smoking in people with stable current or past major depression. Findings showed that varenicline significantly increased continuous abstinence during the last month of treatment and up to a year, without exacerbating depression or anxiety; therefore, it appears to be a well-tolerated and effective treatment for smoking cessation in people with depression.¹⁰¹ A 2017 systematic review and meta-analysis concluded that smoking cessation interventions, particularly pharmacological treatments, appear to increase short-term and long-term smoking abstinence in individuals with current depression, although noted that the evidence is weak.⁹⁹

 7.12.5.2 Anxiety

Despite the high rates of smoking among those with anxiety disorders, there is a dearth of evidence regarding effective cessation interventions for this population.⁶ A randomised controlled trial published in 2011 found that anxiety diagnoses were common among treatment-seeking smokers and were related to increased motivation to smoke, elevated withdrawal, lack of response to pharmacotherapy, and impaired ability to quit smoking.¹⁰² Another study found that smokers with social anxiety disorder experienced higher levels of craving and urge to smoke during quit attempts, which could explain their worse cessation outcomes. Such smokers would likely benefit from additional treatment aimed at managing or reducing their social anxiety symptoms, and NRT also seemed to help alleviate the relationship between social anxiety and cravings.¹⁰³ Overall, further research is needed on how best to support quitting among people with anxiety disorders.⁶

7.12.5.3 Attention-deficit/hyperactivity disorder (ADHD)

ADHD is one of the most common psychiatric disorders, and is associated with a wide range of impairments and risks into adulthood.¹⁰⁴ Smoking is one such risk, with young people with ADHD beginning smoking earlier, and being two to three times more likely to smoke, compared to those without ADHD. The substantially higher prevalence of smoking persists into adulthood, and adults with ADHD are also less likely to be successful at quitting.^105-107

There is a growing body of evidence that stimulant medication, which is a front-line treatment of ADHD, may influence smoking-related outcomes.¹⁰⁵ Nicotine and stimulant medications operate on the same pathways in the brain, and both appear to help alleviate some of the symptoms of ADHD, which may help explain the very high rates of smoking among this group.¹⁰⁸ ADHD medication (i.e., stimulant treatment) reduces smoking rates and smoking withdrawal, therefore early and consistent stimulant treatment of ADHD may reduce smoking risk.^{105, 109} Bupropion, NRT, and possibly varenicline—approved smoking cessation medications—have also shown efficacy in treating symptoms of ADHD;^{109, 110}  however, further research is needed to examine its effectiveness in treating comorbid ADHD-smoking.⁶ Non-pharmacological interventions, particularly cognitive-behavioural therapy, also show promise for the treatment of ADHD, and warrant further investigation for supporting cessation among this population.⁶ Limited evidence also suggests that financial incentives may be a useful approach for promoting short-term cessation in adult smokers with ADHD.¹¹¹

7.12.5.4 Substance use disorders

Smoking prevalence among people with substance use disorders is substantially higher than the general population,^{36, 112, 113} and many people who successfully overcome their substance use disorder will go on to die from a smoking-related disease.¹¹⁴ People with substance or alcohol use disorders have: greater lifetime and current smoking, nicotine dependence, and non-cigarette tobacco use; lower quitting; and differences in quit attempts and withdrawal symptoms compared with people without such disorders.¹¹⁵ Many health risks for dual use of alcohol and tobacco are multiplicative rather than simply additive. For example, the risk of oesophageal cancer is greater among heavy alcohol users as a result of alcohol allowing tobacco toxins to penetrate more deeply to basal layers.¹¹⁶ Similarly, there is evidence that smoking cannabis is a risk factor for many of the same illnesses as tobacco.^117-119 Cannabis poses unique problems for users since it is often mixed with tobacco, potentially inducing double dependence. In 2016, 32% of smokers in Australia reported recent use of cannabis, compared to 7% of non-smokers.(see Chapter 1, Section 1.10) Most people who seek treatment for substance use disorders smoke tobacco as well.¹²⁰ Smoking rates among people in addiction treatment are more than double those of people with similar demographic characteristics.¹¹³ Australian research in the early 2000s found that smoking prevalence in this population ranged from 68–98%^{121, 122} and the 2014–15 National Health Survey also showed extremely high prevalence of smoking among those with harmful use or dependence on alcohol or drugs (see Section 7.12.1). One US review highlights consistently extremely high smoking rates and subsequent comorbid health risk among people with alcohol and drug use disorders, with rates being greatest among those enrolled in methadone maintenance and in-patient addiction treatment.¹²³

Treatment centres for substance use disorders have traditionally not prioritised treating nicotine addiction due to lack of staff training, lack of integration into usual care, and because of the common misperception that quitting may be detrimental to the treatment of alcohol or other drug use.^{124, 126} Substance abuse counsellors often have limited knowledge of the smoking cessation medications available for those trying to quit¹²⁷ and their implementation of tobacco cessation guidelines is inconsistent.¹²⁸ A study of staff and management attitudes and practices in Australia found smoking received little systematic attention, with concerns about possible negative impact on other treatments, absence of policy, and lack of training being major impediments.¹²⁹ Research in the US found that smokers with a substance use disorder who had undergone addiction treatment were less likely to quit smoking than those who had never received such treatment, possibly due to false beliefs about smoking as a coping strategy and staff attitudes that may discourage cessation.¹³⁰ Some centres may even endorse occasional smoking by staff with clients¹³¹ or rely on cigarettes to stabilise mood in their patients.^{39, 132}

Contrary to staff perceptions, smokers with substance use disorders are motivated to quit.¹³³ However, despite this motivation to quit, there appears to be a wide variation in readiness to seek help to do so,^{39, 67, 132, 134} which may be due to a lack of confidence in or wariness of quitting multiple substances at once.¹³⁴ Research in the US showed that when provided with a tobacco free treatment environment, patients with substance abuse and mental illness can and do make the decision to quit tobacco and maintain their abstinence, which in turn helps them to remain sober.¹³⁵ While negative affect can hinder quit attempts, patients in an addictions treatment setting can successfully quit smoking regardless of current depressive symptoms.¹³⁶ In the US, despite being lower than for people without the disorders, the smoking quit rates for people with alcohol use disorders has increased over time.³⁶

Perhaps most importantly, smoking interventions and cessation during substance use treatment appear to enhance rather than compromise long-term abstinence from other addictive drugs.^{9, 137, 139} Including cessation interventions in the course of addiction treatment can increase quit attempts among smokers.^{140, 141} A 2015 systematic review of smoking cessation interventions for adults in substance abuse treatment or recovery concluded that NRT, behavioural support, and combination approaches appear to increase smoking abstinence in those treated for substance use disorders. However, the authors note that higher quality studies are needed to strengthen the evidence base.¹⁴² Some research indicates that drug treatment clients can successfully quit smoking at rates similar to the general population when given access to an intensive intervention.¹⁴³ Several studies suggest that varenicline may promote smoking changes and concurrently help reduce heavy drinking in people with alcohol use disorders.^144-146 However, use of bupropion by abstinent alcoholic smokers does not appear to increase long-term smoking cessation.¹⁴⁷ For methadone maintenance patients, varenicline¹⁴⁸ and NRT¹⁴⁹ may be effective for promoting tobacco abstinence. 

Several studies have explored the role of contingency management (i.e., financial incentives) in promoting abstinence. One study found that contingency management was associated with more short-term abstinence and lowered nicotine addiction among current and former injecting drug users.¹⁵⁰ Another study found that contingent vouchers had limited effects on long-term smoking abstinence among smokers in residential drug treatment, but the effects were improved when vouchers were combined with motivational interviewing.¹⁵¹ A randomised trial similarly found that adding contingency management to an evidence-based smoking cessation treatment that included medication and behavioural counselling doubled the quit rate at the end of treatment among smokers with alcohol abuse or dependence.¹⁵² Contingency management may also promote smoking reduction in more severe substance abusers, such as those in residential services and opioid-maintained patients.^153-155 Such interventions appear to increase abstinence self-efficacy among residential substance abuse treatment patients.¹⁵⁶ Increasing tolerance for withdrawal and abstinence discomfort, addressing expectations, and increasing motivation may also be important when implementing incentive programs.¹⁵⁷ Other strategies include brief advice plus NRT, which appears to be a cost-effective way to reduce smoking for smokers in residential alcohol treatment.¹⁵⁸ A small study found that methadone users responded positively to a computer-based education program highlighting the hazards of smoking.¹⁵⁹

As with mental health and correction services, public health experts have identified a need for policy and training initiatives to address past neglect of tobacco-control issues.^{160, 161} Systematic intervention around the 5As framework, tailored to the needs of client groups, would provide a good foundation for this work. Factors promoting smoking cessation programs within substance abuse clinics include supportive systems and integration within other treatments, educating providers about the beneficial effects of cessation for their clients, staff training, and encouraging and assisting staff to quit.¹³² One study found that an intervention based on organisational change helped to shift the treatment system culture and increase tobacco services in a residential addiction treatment setting.¹⁶¹

Future clinical research in this area and its translation into practice may be improved by recruiting and retaining a broader range of people with drug dependencies, particularly those who are not currently being reached through mainstream interventions, and by longer-term follow-up.¹⁶² Research as to the role of social bonding around tobacco use and its normalisation in drug treatment settings may be useful in guiding future practice.¹³⁴

7.12.5.5 Post-traumatic stress disorder (PTSD)

The prevalence of current smoking in individuals with PTSD is substantially greater than that for the general population, and is estimated to be about 45%. A systematic review concluded that there appears to be a causal relationship between PTSD and smoking that may be bidirectional. PTSD, rather than trauma exposure itself, appears to have a greater influence on a person’s risk of smoking, and specific PTSD symptoms may contribute to smoking and disrupt cessation attempts.¹⁶³ Evidence suggests that people with PTSD smoke to cope with negative affect and anxiety,⁵⁷ and PTSD is associated with higher levels of consumption (i.e., more cigarettes smoked per day).¹⁶⁴ Despite the higher smoking and lower quit rates, there is relatively little research on effective cessation interventions for this population.¹⁶³

To date, there have only been a very small number of randomized clinical trials examining smoking cessation interventions in smokers with PTSD.⁵⁷ Two studies focused on integrating cessation treatment into ongoing mental healthcare, and both found that the integrated care group achieved significantly higher long-term abstinence.^{165, 166} Such integration also appears to be cost-effective.¹⁶⁷ A pilot study with 15 veterans found that bupropion was well-tolerated and effective in helping the participants to quit, with 40% maintaining abstinence.¹⁶⁸ Another small study (N=22) examined the effects of combining contingency management (i.e., monetary rewards) with counselling sessions, NRT, and bupropion. Abstinence rates were higher among the group that received rewards, however the difference was non-significant. This may have been due to the very small sample size, therefore larger studies may help determine the effectiveness of this intervention.¹⁶⁹ A larger randomised controlled trial concluded that integrating motivational interviewing into a PTSD home telehealth care management program is an effective method to help veterans with PTSD quit smoking.¹⁷⁰ A number of case studies suggest that combining cognitive processing therapy with evidence-based smoking cessation interventions may improve both cessation outcomes and PTSD symptoms.¹⁷¹

7.12.5.6 Bipolar disorder

People with bipolar disorder are about three and a half times more likely to smoke than the general population, and have much lower quit rates than smokers without a comorbid condition.^{172, 173} In addition to contributing to increased morbidity and mortality, smoking has also been implicated in the progression of bipolar disorder.¹⁷⁴ However, despite these high rates of comorbidity and related morbidity, there is only a modest field of research focusing on smoking among individuals with bipolar disorder.¹⁷⁵ To date, there have only been a small number of clinical studies on cessation interventions among smokers with bipolar disorder. Researchers have highlighted challenges in recruitment and low eligibility rates as significant hurdles to such studies, and have noted that many health professionals remain wary of encouraging cessation among people with bipolar disorder.¹⁷³ Nonetheless, recent research has attempted to address this gap.

Two very small studies found that buproprion¹⁷⁶ and varenicline¹⁷⁷ were well-tolerated and led to reduced smoking. Subsequent larger studies have also supported the effectiveness of varenicline. The largest study included 247 smokers with schizophrenia or bipolar disorder. Participants received 12-week treatment with both varenicline and cognitive behavioural therapy, and those who had 2 weeks or more of continuous abstinence at week 12 (n=61) were randomly assigned to receive cognitive behavioural therapy and varenicline or placebo from weeks 12 to 52. After a year, those treated with varenicline were more than six times more likely to be abstinent (60%) than those treated with placebo (19%). Importantly, there were no impacts on psychiatric symptoms.¹⁷⁸ Another randomised controlled trial of varenicline included 60 smokers with bipolar disorder. At 3 months (end of treatment), significantly more participants quit smoking with varenicline (48.4%) than with placebo (10.3%). At 6 months, about 19% of those treated with varenicline remained abstinent compared to about 7% assigned to placebo. Psychopathology scores remained stable, although varenicline-treated participants reported significantly more abnormal dreams. The authors call for medication trials of longer duration, and vigilance for neuropsychiatric adverse events.¹⁷⁹

7.12.5.7 Schizophrenia

Schizophrenia is a chronic and severe mental illness that affects about one in 100 people.¹⁸⁰ People with schizophrenia are more than five times more likely to smoke than the general population,²¹ and tobacco-related conditions are responsible for about half of total deaths in people with schizophrenia.¹⁸¹ Rates of cessation for smokers with schizophrenia are half those for the general population, partly because of their lower motivation to quit, fewer cessation attempts, increased level of nicotine dependence, and reduced access to treatments.¹⁸² They may also perceive themselves to be at lower risk of smoking related-disease.¹⁸³ Healthcare services have traditionally condoned or encouraged smoking and failed to offer tobacco cessation interventions to patients with schizophrenia, mainly due to beliefs about the benefits of smoking to symptoms, stigma, lack of information, or perceived hopelessness regarding abstinence.^{184, 185} However, in recent times there has been considerable interest in developing effective smoking treatment for this population,⁶ and guidelines have been published that include cessation interventions for smokers with schizophrenia.⁸⁵ Smokers with a psychotic disorder are capable of long-term reduction and abstinence with appropriate intervention and support.¹⁸⁶ Once people with schizophrenia have successfully quit, the use of antipsychotics may need to be reviewed, as tobacco smoke can differentially affect drug metabolism and the effects of antipsychotic medications.^8, 187

A 2013 Cochrane review of interventions for smoking cessation and reduction in individuals with schizophrenia concluded that bupropion increases smoking abstinence rates in smokers, without any deterioration of mental state. Varenicline may also improve smoking cessation rates, but the authors noted a possibility of adverse psychiatric effects, such as increased suicidality. There is some evidence that contingent reinforcement (i.e., monetary rewards) may help people with schizophrenia to quit and reduce smoking in the short term.¹⁸⁵ Building on the Cochrane review, a 2015 systematic review and meta-analysis examined the evidence regarding varenicline for smoking cessation in people with schizophrenia. It concluded that while there did not appear to be any adverse psychiatric outcomes, varenicline was not found to be superior to placebo for quitting.¹⁸⁸ Another 2015 review of smoking cessation in people with schizophrenia concluded that the most promising evidence is for bupropion, and that pharmacological interventions do not appear to increase adverse events. It suggested that the lack of evidence for NRT and varenicline may be due to the paucity of research. Behavioural and psychosocial interventions are also promising, particularly when combined with pharmacotherapy. The authors highlight the importance of carefully monitoring antipsychotic levels, and suggest that encouraging physical activity may help to negate potential weight gain and diabetes risk following cessation.¹⁸⁹ A further review of the evidence recommended that people with schizophrenia should receive varenicline or bupropion with or without nicotine replacement therapy in combination with behavioural treatment. Maintenance pharmacotherapy for 1 year appears to improve sustained abstinence rates.¹⁹⁰

Results from a large randomised controlled trial were published in 2016, which found that varenicline was more effective than bupropion and nicotine patch in smokers both with and without psychiatric disorders (including schizophrenia), whereas bupropion and nicotine patch were similarly effective, and both more so than placebo. The authors also examined the safety of the medications, and concluded that they can be used safely by psychiatrically stable smokers; there was no increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo.⁸⁸ In September 2016, the FDA released a preliminary review of this trial, suggesting a number of problems with the study. The review supported similar conclusions about the relative rates of events: in patients without prior psychiatric history, events did not seem to be more frequent in varenicline, bupropion, or NRT-treated patients than in placebo-treated patients. The review also found that among patients attempting to quit, events were more common in those with psychiatric history than those without, regardless of which treatment they received. Of concern however, was a possible increased risk of neuropsychiatric events in patients with psychiatric history in the varenicline or bupropion group compared to placebo. This trended toward statistical significance, but was not observed in NRT-treated patients.¹⁹¹

Additional recent randomised controlled trials^{192, 193} and a systematic review and meta-analysis¹⁹⁴ have supported the safety and efficacy of varenicline for reducing smoking in people with schizophrenia. A 2017 review recommends that smokers with schizophrenia should receive varenicline, bupropion with or without NRT, or NRT, all in combination with behavioural treatment for at least 12 weeks. Maintenance pharmacotherapy may reduce relapse and improve sustained abstinence rates. It notes that controlled trials in smokers with schizophrenia consistently show no greater rate of neuropsychiatric adverse events with pharmacotherapies than with placebo.¹⁹⁵

7.12.6 Role of health professionals and health settings

Medical and mental health professionals often overlook the importance of addressing tobacco use with their patients.^{38, 196} Smoking is often not asked about or recorded as a standard part of psychiatric assessment, and even when it is, inclusion of smoking cessation in treatment planning is often inconsistent.^{38, 197-199}This may be partly due to the erroneous beliefs held by some mental health workers that smoking is one of the few pleasures clients have, that smoking reduces stress and anxiety,^{44, 200} that those with mental illness are not motivated to quit,⁷² or that there are more pressing concerns for patients with acute psychiatric symptoms.⁵⁶

International evidence suggests that cessation support for inpatient smokers by staff is likely to be severely compromised by low levels of knowledge and awareness of tobacco dependence.²⁰¹  Several Australian surveys have found strong support for the provision of smoking cessation treatment among mental health service staff;^{202, 203} however staff report significant barriers to providing such care.²⁰² Commonly cited barriers include inadequate resources, cultural norms, client resistance, and lack of training and confidence.^204-206 More experienced staff, and those with tobacco cessation training, are more likely to help their clients quit smoking.^{207, 199,  208}

Healthcare professionals, including physicians, psychiatrists, and psychologists, have an important role in the recognition and treatment of tobacco use disorders in patients with psychiatric illnesses, and providing cessation treatment for all patients with a co-occurring tobacco use disorder should form part of routine care.^{8, 209, 210} A 2015 systematic review and meta-analysis concluded that while there has been progress, offering smoking cessation advice should receive a higher priority in everyday clinical practice for patients with a mental health diagnosis.²¹¹ Encouraging longitudinal research in the US found that smokers who had seen mental health professionals for mental health problems had higher odds of having made attempts to quit in the past year, and were more likely to have used cessation assistance.²¹² However, another longitudinal US study looking only at psychiatrists found that they are screening for tobacco use at declining rates, and the proportion of smokers provided with treatment remains low.²¹³

As in the general population, people with mental illness should be given advice and support to quit using the 5As framework.²¹⁴ Given that people with mental illness are often highly nicotine dependent, and are more likely to socialise with smokers, more intensive interventions may have greater success. This might involve NRT or other pharmacotherapies, as well as referral to a specialised individual program, such as the Quitline, or a group program. The integration of cessation treatment into existing care by health professionals results in greater engagement, greater use of cessation pharmacotherapy, and increased likelihood of abstinence.¹⁶⁵ Quit Victoria has suggested a number of strategies that mental health services could implement to reduce smoking-related harms, including:

• routinely asking clients about their smoking and recording responses
• referring clients and staff to Quitline, a doctor, or a local quit smoking program
• establishing or reviewing smokefree policy
• encouraging staff to complete further training in smoking cessation
• displaying posters and print resources
• referring staff and clients to the Quit website for information on services and smoking care medications.²¹⁵

An important part of providing smoking cessation support for those with mental health disorders is for mental health services to develop comprehensive policy on smokefree environments, documenting tobacco use, and continuing support on discharge. This requires leadership from management, staff training, and consistency across services.^{216,  217} An audit of an Australian psychiatric hospital found that the setting did not conform to current clinical practice guidelines as it often failed to document smoking status, despite nicotine dependence being the most commonly diagnosed psychiatric disorder.²¹⁸ Another Australian study of public psychiatric inpatient units found that over one-third of inpatients started smoking during their admission, and that staff often provided cigarettes to patients. Only half of respondents reported that all patients were assessed for smoking status. The study suggests that failure of psychiatric services to provide smoking care is systematic and not related to particular types of services.²¹⁹

Some psychiatric services have become smokefree²²⁰ and there is evidence that hospitalisation in a smokefree environment is associated with increases in patients’ expectancies about quitting and staying a non-smoker,²²¹ and with reduction in cigarette consumption.²²² A systematic review concluded that smokefree psychiatric hospitalisation may have a positive impact on patients' smoking-related behaviours, motivation, and beliefs, both during admission and up to 3 months post discharge.²²³ During smokefree psychiatric hospitalisations, offering patients NRT directly on admission, educating patients on the benefits of NRT, and increasing the dosage for more dependent smokers can help with managing nicotine withdrawal.²²⁴ Community support post-discharge may also help smokers to maintain abstinence.²²⁵ Psychiatric hospitals in the US that voluntarily adopted such bans have documented little-to-no disturbance in patients’ behaviour and time savings for staff members.⁵⁶ A study in France found that staff members of a psychiatric facility were exposed to substantially lower levels of secondhand smoke post-ban.²²⁶ However, an Australian study published in 2015 found that adherence to smokefree policy in an inpatient psychiatric facility was poor, with more than four in five smokers still smoking, and only about half perceiving staff to be supportive of the policy.²²⁷ Two Australian studies have found that about only about half of psychiatric patients feel positively about bans,^{227, 228} while another found that only about one quarter of mental health staff agreed with a total smoking ban.²²⁹ Some patients also perceive the restrictions to be a form of punishment.²³⁰ There have been debates recently regarding the ethics of implementing complete smoking bans in psychiatric hospitals; proponents argue that the ‘smoking culture’ creates disproportionate harm among people with mental illness, while opponents argue that it is unethical to deprive patients of autonomy and impose treatment.^{231, 232}

Together, evidence suggests that there is a critical need to engage healthcare providers, policy-makers, and mental health advocates in the effort to increase access to:

• evidence-based tobacco treatment for smokers with mental health disorders
• smokefree environments for mental health treatment
• training for clinicians in cessation treatment
• systems for routinely identifying patients who smoke, advising cessation and providing treatment or referral.⁵⁶
• 
  

  Relevant news and research

  For recent news items and research on this topic, click here.(Last updated May 2019)

References

1. Cooper J, Mancuso SG, Borland R, Slade T, Galletly C, et al. Tobacco smoking among people living with a psychotic illness: The second Australian survey of psychosis. Australian and New Zealand Journal of Psychiatry, 2012; 46(9):851–63. Available from: http://anp.sagepub.com/content/46/9/851.abstract

2. Williams JM, Steinberg ML, Griffiths KG, and Cooperman N. The need for smokers with behavioral health comorbidity to be designated as a tobacco use disparity group. American Journal of Public Health, 2013; 103(9):1549–55. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776478/

3. Forman-Hoffman VL, Hedden SL, Glasheen C, Davies C, and Colpe LJ. The role of mental illness on cigarette dependence and successful quitting in a nationally representative, household-based sample of US adults. Annals of Epidemiology, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27247163

4. Lawrence D, Hancock KJ, and Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: Retrospective analysis of population based registers. British Medical Journal, 2013; 346. Available from: http://www.bmj.com/bmj/346/bmj.f2539.full.pdf

5. Tam J, Warner KE, and Meza R. Smoking and the reduced life expectancy of individuals with serious mental illness. American Journal of Preventive Medicine, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27522471

6. Minichino A, Bersani FS, Calo WK, Spagnoli F, Francesconi M, et al. Smoking behaviour and mental health disorders--mutual influences and implications for therapy. International Journal of Environmental Research and Public Health, 2013; 10(10):4790–811. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24157506

7. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, et al. Change in mental health after smoking cessation: Systematic review and meta-analysis. British Medical Journal, 2014; 348:g1151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24524926

8. Mendelsohn CP, Kirby DP, and Castle DJ. Smoking and mental illness. An update for psychiatrists. Australas Psychiatry, 2015; 23(1):37–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25512967

9. Prochaska JJ. Failure to treat tobacco use in mental health and addiction treatment settings: A form of harm reduction? Drug and Alcohol Dependence, 2010; 110(3):177–82. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916693/

10. Australian Institute of Health and Welfare. National Drug Strategy Household Survey (NDSHS) 2016 key findings data tables. Canberra: AIHW, 2017. Available from: https://www.aihw.gov.au/reports/illicit-use-of-drugs/2016-ndshs-detailed/data.

11. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, et al. People living with psychotic illness:  An Australian study 1997−98. Mental Health Branch, Commonwealth Department of Health and Aged Care.Canberra 1999.

12. Australian Institute for Health and Welfare, National Drug Strategy Household Survey, 2016 [computer file]. Canberra: Australian Data Archive, The Australian National University; 2017.

13. Australian Bureau of Statistics. TableBuilder. Available from: http://www.abs.gov.au/websitedbs/d3310114.nsf/home/about+tablebuilder

14. Australian Bureau of Statistics. 4364.0.55.001–National Health Survey: First results, 2014–15  Available from: http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4364.0.55.001~2014-15~Main%20Features~Key%20findings~1

15. Smith PH, Mazure CM, and McKee SA. Smoking and mental illness in the US population. Tobacco Control, 2014; 23(e2):e147–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24727731

16. Ziedonis D, Hitsman B, Beckham J, Zvolensky M, Adler L, et al. Tobacco use and cessation in psychiatric disorders: National institute of mental health report. Nicotine & Tobacco Research, 2008; 10(12):1691–715. Available from: http://www.informaworld.com/smpp/content~db=all?content=10.1080/14622200802443569

17. Sung H, Prochaska J, Ong M, Shi Y, and Max W. Cigarette smoking and serious psychological distress: A population-based study of California adults. Nicotine & Tobacco Research, 2011; 13(12):1183–92. Available from: http://ntr.oxfordjournals.org/content/early/2011/08/17/ntr.ntr148.full

18. Lasser K, Boyd L, Woolhandler S, Himmelstein S, McCormick D, et al. Smoking and mental illness: A population-based prevalence study. Journal of the American Medical Association, 2000; 284(2):2606–10. Available from: http://jama.ama-assn.org/cgi/content/full/284/20/2606

19. Grant BF, Hasin DS, Chou SP, Stinson FS, and Dawson DA. Nicotine dependence and psychiatric disorders in the United States: Results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry, 2004; 61(11):1107–15. Available from: 

http://www.ncbi.nlm.nih.gov/pubmed/15520358

 

20. Public Health England, Smoking cessation in secure mental health settings. London 2015. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/432222/Smoking_Cessation_in_Secure_Mental_Health_Settings_-_guidance_for_commis....pdf.

21. de Leon J and Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research, 2005; 76(2–3):135–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15949648

22. Dehay T, Morris C, May M, Devine K, and Waxmonsky J. Tobacco use in youth with mental illnesses. Journal of Behavioral Medicine, 2012; 35(2):139–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21479646  

23. Kollins SH, McClernon F, and Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Archives of General Psychiatry, 2005; 62(10):1142–47. Available from: http://dx.doi.org/10.1001/archpsyc.62.10.1142

24. Australian Institute of Health and Welfare. National Drug Strategy Household Survey detailed report: 2013. Cat. no. PHE 183 Canberra: AIHW, 2014. Available from: http://www.aihw.gov.au/publication-detail/?id=60129549469&tab=3.

25. Ashton M, Miller C, Bowden J, and Bertossa S. People with mental illness can tackle tobacco. The Australian and New Zealand Journal of Psychiatry, 2010; 44(11):1021–8. Available from: http://informahealthcare.com/doi/pdf/10.3109/00048674.2010.497753

26. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, et al. Characteristics of smokers with a psychotic disorder and implications for smoking interventions. Psychiatry Research, 2007; 150(2):141–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17289155

27. Williams J and Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addictive Behaviors, 2004; 29(6):1067–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15236808

28. Williams J, Gandhi K, Lu S, Kumar S, Steinberg M, et al. Shorter interpuff interval is associated with higher nicotine intake in smokers with schizophrenia. Drug and Alcohol Dependence, 2011; 118(2–3):313–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21596491  

29. Khaled S, Bulloch A, Williams J, Lavorato D, and Patten S. Major depression is a risk factor for shorter time to first cigarette irrespective of the number of cigarettes smoked per day: Evidence from a national population health survey. Nicotine & Tobacco Research, 2011; 13(11):1059–67. Available from: http://ntr.oxfordjournals.org/content/early/2011/08/10/ntr.ntr157.full

30. Lawrence D and Williams JM. Trends in smoking rates by level of psychological distress-time series analysis of US national health interview survey data 1997-2014. Nicotine & Tobacco Research, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26705303

31. Steinberg ML, Williams JM, and Li Y. Poor mental health and reduced decline in smoking prevalence. American Journal of  Preventive Medicine, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26071864

32. Weinberger AH, Gbedemah M, Wall MM, Hasin DS, Zvolensky MJ, et al. Cigarette use is increasing among people with illicit substance use disorders in the United States, 2002-14: Emerging disparities in vulnerable populations. Addiction, 2017. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29265574

33. Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, et al. Cigarette smoking by patients with serious mental illness, 1999-2016: An increasing disparity. Psychiatric Services, 2017:appips201700118. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28945183

34. Zvolensky MJ, Jardin C, Wall MM, Gbedemah M, Hasin D, et al. Psychological distress among smokers in the United States: 2008 to 2014. Nicotine & Tobacco Research, 2017. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28482108

35. Kulik MC and Glantz SA. Softening among u.S. Smokers with psychological distress: More quit attempts and lower consumption as smoking drops. American Journal of Preventive Medicine, 2017. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29029966

36. Weinberger AH, Gbedemah M, and Goodwin RD. Cigarette smoking quit rates among adults with and without alcohol use disorders and heavy alcohol use, 2002-2015: A representative sample of the United States population. Drug and Alcohol Dependence, 2017; 180:204–7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28918239

37. Australian Bureau of Statistics. 4364.0.55.001 - Australian Health Survey: First Results, 2011–12, 2012. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/lookup/4364.0.55.001main+features12011-12

38. Ragg M and Ahmed T, Smoke and mirrors: A review of the literature on smoking and mental illness. Tackiling tobacco program research series no 1 Sydney: Cancer Council NSW; 2008. Available from: http://www.cancerdirectory.com.au/resource/view?slug=Smoke-and-Mirrors-A-review-of-the-literature-on-smoking-and-mental-illness&page=1 .

39. Hall S and Prochaska J. Treatment of smokers with co-occurring disorders: Emphasis on integration in mental health and addiction treatment settings. Annual Review of Clinical Psychology, 2009; 5:409–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19327035

40. Lawn S and Pols R. Nicotine withdrawal: Pathway to aggression and assault in the locked psychiatric ward? Australasian Psychiatry, 2003; 11(2):199–203. Available from: http://apy.sagepub.com/content/11/2/199.abstract

41. Olivier D, Lubman D, and Fraser R. Tobacco smoking within psychiatric inpatient settings: Biopsychosocial perspective. Australia and New Zealand Journal of Psychiatry, 2007; 41(7):572–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17558619

42. Dwyer T, Bradshaw J, and Happell B. Comparison of mental health nurses' attitudes towards smoking and smoking behaviour. International Journal of Mental Health Nursing, 2009; 18(6):424–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19883414

43. Aubin H-J, Rollema H, Svensson TH, and Winterer G. Smoking, quitting, and psychiatric disease: A review. Neuroscience & Biobehavioral Reviews, 2012; 36(1):271–84. Available from: http://www.sciencedirect.com/science/article/pii/S0149763411001175

44. Reilly P, Murphy L, and Alderton D. Challenging the smoking culture within a mental health service supportively. International Journal of Mental Health Nursing, 2006; 15(4):272–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17064324

45. Peckham E, Bradshaw TJ, Brabyn S, Knowles S, and Gilbody S. Exploring why people with SMI smoke and why they may want to quit: Baseline data from the SCIMITAR RCT. Journal of Psychiatric and Mental Health Nursing, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26147943

46. Trainor K and Leavey G. Barriers and facilitators to smoking cessation among people with severe mental illness: A critical appraisal of qualitative studies. Nicotine & Tobacco Research, 2016. Available from: http://ntr.oxfordjournals.org/content/early/2016/08/11/ntr.ntw183.abstract

47. Morisano D, Bacher I, Audrain-McGovern J, and George T. Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Canadian Journal of Psychiatry, 2009; 54(6):356–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19527556

48. Manzella F, Maloney SE, and Taylor GT. Smoking in schizophrenic patients: A critique of the self-medication hypothesis. World Journal of Psychiatry, 2015; 5(1):35–46. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369547/

49. Boggs DL, Surti TS, Esterlis I, Pittman B, Cosgrove K, et al. Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. Schizophrenia Research, 2017. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28392208

50. Kassel JD, Stroud L, and Paronis C. Smoking, stress and negative affect: Correlation, causation and context across stages of smoking. Psychological Bulletin, 2003; 192(2):270–304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12696841

51. Poorolajal J and Darvishi N. Smoking and suicide: A meta-analysis. PLoS ONE, 2016; 11(7):e0156348. Available from: http://dx.doi.org/10.1371%2Fjournal.pone.0156348

52. Yaworski D, Robinson J, Sareen J, and Bolton JM. The relation between nicotine dependence and suicide attempts in the general population. Canadian Journal of Psychiatry, 2011; 56(3):161–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21443823

53. Sankaranarayanan A and Castle D. Burden associated with smoking as a suicidal risk factor in an Australian sample of patients with psychosis. Australas Psychiatry, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27130725

54. Sankaranarayanan A, Clark V, Baker A, Palazzi K, Lewin TJ, et al. Reducing smoking reduces suicidality among individuals with psychosis: Complementary outcomes from a healthy lifestyles intervention study. Psychiatry Res, 2016; 243:407–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27450743

55. Gurillo P, Jauhar S, Murray RM, and MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. The Lancet Psychiatry, 2015; 2(8):718–25. Available from: http://dx.doi.org/10.1016/S2215-0366(15)00152-2

56. Prochaska J. Smoking and mental illness--breaking the link. The New England Journal of Medicine, 2011; 365(3):196–8. Available from: http://www.nejm.org/doi/full/10.1056/NEJMp1105248

57. Tidey JW and Miller ME. Smoking cessation and reduction in people with chronic mental illness. British Medical Journal, 2015; 351:h4065. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26391240

58. Jenkins R, Bhugra D, Bebbington P, Brugha T, Farrell M, et al. Debt, income and mental disorder in the general population. Psychological Medicine, 2008; 38(10):1485–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18184442

59. Department of Health, National mental health report. Australian Government; 2013. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/mental-pubs-n-report13 .

60. Lawn S, Hersh D, Ward P, Tsourtos G, Muller R, et al. 'I just saw it as something that would pull you down, rather than lift you up': Resilience in never-smokers with mental illness. Health Education Research, 2011; 26(1):26–38. Available from: http://her.oxfordjournals.org/content/early/2010/11/09/her.cyq065.full.pdf

61. Twyman L, Bonevski B, Paul C, and Bryant J. Perceived barriers to smoking cessation in selected vulnerable groups: A systematic review of the qualitative and quantitative literature. BMJ Open, 2014; 4(12):e006414. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25534212

62. Lawn S. Systematic barriers to quitting smoking among institutionalised public mental health service populations: A comparison of two Australian sites. The International Journal of Social Psychiatry, 2004; 50(3):201–15. Available from: http://isp.sagepub.com/cgi/content/abstract/50/3/204

63. Sundgren E, Hallqvist J, and Fredriksson L. Health for smokers with schizophrenia - a struggle to maintain a dignified life. Disability and Rehabilitation, 2015:1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25958996

64. Ragg M, Gordon R, Ahmed T, and Allan J. The impact of smoking cessation on schizophrenia and major depression. Australasian Psychiatry, 2013; 21(3):238–45. Available from: http://apy.sagepub.com/content/21/3/238.abstract

65. Banham L and Gilbody S. Smoking cessation in severe mental illness: What works? Addiction, 2010; 105(7):1176–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20491721

66. Bolam B, West R, and Gunnell D. Does smoking cessation cause depression and anxiety? Findings from the attempt cohort. Nicotine & Tobacco Research, 2011; 13(3):209–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21330275

67. Prochaska JJ, Delucchi K, and Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. Journal of Consulting and Clinical Psychology, 2004; 72(6):1144–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15612860

68. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, et al. Does treatment of attention deficit hyperactivity disorder (ADHD) enhance response to smoking cessation intervention in ADHD smokers? A randomized trial. The Journal of Clinical Psychiatry, 2010; 71(12):1680–8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151610/

69. Covey LS, Hu M-C, Winhusen T, Weissman J, Berlin I, et al. Oros-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: Racial/ethnic differences. Drug and Alcohol Dependence, 2010; 110(1-2):156–9. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913299/

70. Covey LS, Hu MC, Winhusen T, Lima J, Berlin I, et al. Anxiety and depressed mood decline following smoking abstinence in adult smokers with attention deficit hyperactivity disorder. Journal of Substance Abuse Treatment, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26272693

71. Hitsman B, Borrelli B, McChargue DE, Spring B, and Niaura R. History of depression and smoking cessation outcome: A meta-analysis. Journal of Consulting and Clinical Psychology, 2003; 71(4):657–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12924670

72. Siru R, Hulse GK, and Tait RJ. Assessing motivation to quit smoking in people with mental illness: A review. Addiction, 2009; 104(5):719–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19413788

73. Brown CH, Medoff D, Dickerson FB, Fang LJ, Lucksted A, et al. Factors influencing implementation of smoking cessation treatment within community mental health centers. Journal of Dual Diagnosis, 2015; 11(2):145–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25985201

74. Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, et al. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. Journal of the American Medical Association, 2014; 311(2):172–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24399556

75. Tidey JW, Colby SM, and Xavier EM. Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia. Nicotine & Tobacco Research, 2014; 16(3):326–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24113929

76. Anzai N, Young-Wolff KC, and Prochaska JJ. Symptom severity and readiness to quit among hospitalized smokers with mental illness. Psychiatric Services, 2015; 66(4):443–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25828988

77. McNeill A. Smoking and mental health: A review of the literature. London: Smokefree London Programme, 2001. Available from: http://www.ash.org.uk/html/policy/menlitrev.pdf

78. Morris CD, Burns EK, Waxmonsky JA, and Levinson AH. Smoking cessation behaviors among persons with psychiatric diagnoses: Results from a population-level state survey. Drug and Alcohol Dependence, 2014; 136:63–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24417963

79. Siru R, Hulse G, Khan R, and Tait R. Motivation to quit smoking among hospitalised individuals with and without mental health disorders. The Australian and New Zealand Journal of Psychiatry, 2010; 44(7):640–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20560851

80. Moeller-Saxone K. Cigarette smoking and interest in quitting among consumers at a psychiatric disability rehabilitation and support service in Victoria. Australian and New Zealand Journal of Public Health, 2008; 32(5):479–81. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1753-6405.2008.00283.x/abstract

81. Young-Wolff KC, Fromont SC, Delucchi K, Hall SE, Hall SM, et al. PTSD symptomatology and readiness to quit smoking among women with serious mental illness. Addictive Behaviors, 2014; 39(8):1231–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24813548

82. Dickerson F, Bennett M, Dixon L, Burke E, Vaughan C, et al. Smoking cessation in persons with serious mental illnesses: The experience of successful quitters. Psychiatric Rehabilitation Journal, 2011; 34(4):311–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21459747  

83. Hitsman B, Moss T, Montoya I, and George T. Treatment of tobacco dependence in mental health and addictive disorders. Canadian Journal of Psychiatry, 2009; 54(6):368–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19527557

84. Cavazos-Rehg PA, Breslau N, Hatsukami D, Krauss MJ, Spitznagel EL, et al. Smoking cessation is associated with lower rates of mood/anxiety and alcohol use disorders. Psychological Medicine, 2014; 44(12):2523–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25055171

85. The Royal Australian College of General Practitioners, Supporting smoking cessation: A guide for health professionals. Melbourne: RACGP; 2014. Available from: http://www.racgp.org.au/your-practice/guidelines/smoking-cessation/.

86. Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, et al. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: A review of reviews for the US Preventive Services Task Force. Annals of Internal Medicine, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26389650

87. Oliveira P, Ribeiro J, Donato H, and Madeira N. Smoking and antidepressants pharmacokinetics: A systematic review. Annals of General Psychiatry, 2017; 16:17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28286537

88. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27116918

89. Stockings EA, Bowman JA, Baker AL, Terry M, Clancy R, et al. Impact of a postdischarge smoking cessation intervention for smokers admitted to an inpatient psychiatric facility: A randomized controlled trial. Nicotine & Tobacco Research, 2014; 16(11):1417–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24939916

90. SANE Australia. Smoking cessation in long term psychiatric patients. Melbourne: SANE Australia.

91. Quit South Australia, The Tobacco and Mental Illness Project, and The Queen Elizabeth Hospital and Health Service, 'I’m giving it a go'.  A step-by-step guide for people with mental illness who smoke and want to cut down or quit. Adelaide, SA: Quit South Australia; 2004.

92. Bertossa S. You can do it! A positive approach to supporting people to address tobacco. The Mental Health Services Conference, Sydney, 2005. 

93. Quit Group. Minimum standards for Australian quitline services, 2007.

94. van der Meer RM, Willemsen MC, Smit F, and Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database of Systematic Reviews, 2013; 8:Cd006102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23963776

95. Weinberger AH, Pilver CE, Desai RA, Mazure CM, and McKee SA. The relationship of major depressive disorder and gender to changes in smoking for current and former smokers: Longitudinal evaluation in the US population. Addiction, 2012; 107(10):1847–56. Available from: http://dx.doi.org/10.1111/j.1360-0443.2012.03889.x

96. van der Meer RM, Willemsen MC, Smit F, and Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database of Systematic Reviews, 2006; 3:CD006102. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006102/abstract

97. Cooper J, Borland R, McKee SA, Yong HH, and Dugue PA. Depression motivates quit attempts but predicts relapse: Differential findings for gender from the International Tobacco Control Study. Addiction, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26888199

98. Morozova M, Rabin RA, and George TP. Co-morbid tobacco use disorder and depression: A re-evaluation of smoking cessation therapy in depressed smokers. American Journal on Addictions, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26354720

99. Secades-Villa R, Gonzalez-Roz A, Garcia-Perez A, and Becona E. Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: A systematic review and meta-analysis. PLoS ONE, 2017; 12(12):e0188849. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29206852

100. Gierisch J, Bastian L, Calhoun P, McDuffie J, Williams J, et al. Comparative effectiveness of smoking cessation treatments for patients with depression: A systematic review and meta-analysis of the evidence, Department of Veterans Affairs, Veterans Health Administration, and Health Services Research & Development Service, Editors. 2010. Available from: http://www.ncbi.nlm.nih.gov/books/NBK51226/pdf/TOC.pdf.

101. Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depressiona randomized trial. Annals of Internal Medicine, 2013; 159(6):390–400. Available from: http://dx.doi.org/10.7326/0003-4819-159-6-201309170-00005

102. Piper ME, Cook JW, Schlam TR, Jorenby DE, and Baker TB. Anxiety diagnoses in smokers seeking cessation treatment: Relations with tobacco dependence, withdrawal, outcome, and response to treatment. Addiction, 2011; 106(2):418–27. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017215/

103. Kimbrel NA, Morissette SB, Gulliver SB, Langdon KJ, and Zvolensky MJ. The effect of social anxiety on urge and craving among smokers with and without anxiety disorders. Drug and Alcohol Dependence, 2014; 135:59–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24331637

104. Willcutt EG. The prevalence of DSM-iv attention-deficit/hyperactivity disorder: A meta-analytic review. Neurotherapeutics, 2012; 9(3):490–9. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441936/

105. Schoenfelder EN, Faraone SV, and Kollins SH. Stimulant treatment of ADHD and cigarette smoking: A meta-analysis. Pediatrics, 2014; 133(6):1070–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24819571

106. McClernon FJ and Kollins SH. ADHD and smoking: From genes to brain to behavior. Annals of the New York Academy of Sciences, 2008; 1141:131–47. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758663/

107. Lee SS, Humphreys KL, Flory K, Liu R, and Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review. Clinical Psychology Review, 2011; 31(3):328–41. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180912/

108. US Department of Health and Human Services. The health consequences of smoking: A report of the Surgeon General. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. Available from: http://www.cdc.gov/tobacco/data_statistics/sgr/index.htm.

109. van Amsterdam J, van der Velde B, Schulte M, and van den Brink W. Causal factors of increased smoking in ADHD: A systematic review. Substance Use and Misuse, 2017:1–14. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29039714

110. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry, 2001; 158(2):282–8. Available from: http://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.158.2.282

111. Kollins S, McClernon F, and Van Voorhees E. Monetary incentives promote smoking abstinence in adults with attention deficit hyperactivity disorder (ADHD). Experimental and Clinical Psychopharmacology, 2010; 18(3):221–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20545386

112. Baker A, Ivers RG, Bowman J, Butler T, Kay-Lambkin FJ, et al. Where there's smoke, there's fire: High prevalence of smoking among some sub-populations and recommendations for intervention. Drug and Alcohol Review, 2006; 25(1):85–96. Available from: http://dx.doi.org/10.1080/09595230500459552

113. Guydish J, Passalacqua E, Pagano A, Martinez C, Le T, et al. An international systematic review of smoking prevalence in addiction treatment. Addiction, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26392127

114. Hurt RD, Offord KP, Croghan IT, GomezDahl L, Kottke TE, et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. Journal of the American Medical Association, 1996; 275(14):1097–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8601929

115. Weinberger AH, Funk AP, and Goodwin RD. A review of epidemiologic research on smoking behavior among persons with alcohol and illicit substance use disorders. Preventive Medicine, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27196143

116. Bien T and Burge R. Smoking and drinking: A review of the literature. International Journal of Addiction, 1990; 25(12):1429–54. Available from: http://www.informaworld.com/smpp/content~content=a786595399~db=all

117. Hashibe M, Straif K, Tashkin D, Morgenstern H, Greenland S, et al. Epidemiological review of marijuana use and cancer risk. Alcohol, 2005; 35(3):265–75. 

118. Ashton C. Adverse effects of cannabis and cannabinoids. British Journal of Anaesthesia, 1999; 83(4):637–49. Available from:http://bja.oxfordjournals.org/cgi/content/citation/83/4/637

119. Kalant H. Adverse effects of cannabis on health: An update of the literature since 1996. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2004; 28(849−63). 

120. Baker A, Ivers R, Bowman J, Butler T, Kay-Lambkin F, et al. Where there's smoke, there's fire: High prevalence of smoking among some sub-populations and recommendations for intervention. Drug and Alcohol Review, 2006; 25:85–96. Available from: http://www.informaworld.com/smpp/content~content=a741424195~db=all~order=page

121. Degenhardt L and Hall W. Patterns of co-morbidity between alcohol use and other substance use in the Australian population. Drug and Alcohol Review, 2003; 22(1):7–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12745353

122. Reichler H, Baker A, Lewin T, and Carr V. Smoking among in-patients with drug-related problems in an Australian psychiatric hospital. Drug and Alcohol Review, 2001; 20(2):231–7. Available from: http://www.informaworld.com/smpp/content~content=a713659508~db=all~order=page

123. Guydish J, Passalacqua E, Tajima B, Chan M, Chun J, et al. Smoking prevalence in addiction treatment: A review. Nicotine & Tobacco Research, 2011; 13(6):401–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21464202  

124. Guydish J, Passalacqua E, Tajima B, and Manser ST. Staff smoking and other barriers to nicotine dependence intervention in addiction treatment settings: A review. Journal of Psychoactive Drugs, 2007; 39(4):423–33. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993183/

125. Fuller BE, Guydish J, Tsoh J, Reid MS, Resnick M, et al. Attitudes toward the integration of smoking cessation treatment into drug abuse clinics. Journal of Substance Abuse Treatment, 2007; 32(1):53–60. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496385/

126. Gentry S, Craig J, Holland R, and Notley C. Smoking cessation for substance misusers: A systematic review of qualitative studies on participant and provider beliefs and perceptions. Drug and Alcohol Dependence, 2017; 180:178–92. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28910690

127. Rothrauff T and Eby L. Counselors' knowledge of the adoption of tobacco cessation medications in substance abuse treatment programs. American Journal on Addictions, 2011; 20(1):56–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21175921

128. Rothrauff T and Eby L. Substance abuse counselors' implementation of tobacco cessation guidelines. Journal of Psychoactive Drugs, 2011; 43(1):6–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21615002

129. Walsh R, Bowman J, Tzelepis F, and Lecathelinais C. Smoking cessation interventions in Australian drug treatment agencies: A national survey of attitudes and practices. Drug and Alcohol Review, 2005; 24(3):235–44. Available from: http://www.informaworld.com/smpp/content~db=all?content=10.1080/09595230500170282

130. Shu C and Le Cook B. Examining the association between substance use disorder treatment and smoking cessation. Addiction, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25683883

131. Walsh R, Bowman J, Tzelepis F, and Lecathelinais C. Regulation of environmental tobacco smoke by Australian drug treatment agencies. Australian and New Zealand Journal of Public Health, 2005; 29(3):276–8. Available from: http://www3.interscience.wiley.com/journal/118740098/abstract

132. Baca C and Yahne C. Smoking cessation during substance abuse treatment: What you need to know. Journal of Substance Abuse Treatment, 2008; 36(2):205–19. Available from: http://www.journalofsubstanceabusetreatment.com/article/S0740-5472(08)00097-4/abstract

133. Cookson C, Strang J, Ratschen E, Sutherland G, Finch E, et al. Smoking and its treatment in addiction services: Clients' and staff behaviour and attitudes. BMC Health Services Research, 2014; 14:304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25017205

134. Toussaint DW, VanDeMark NR, Silverstein M, and Stone E. Exploring factors related to readiness to change tobacco use for clients in substance abuse treatment. Journal of Drug Issues, 2009; 39(2). Available from: http://www.encyclopedia.com/doc/1P3-1826120721.html

135. Stuyt EB. Enforced abstinence from tobacco during in-patient dual-diagnosis treatment improves substance abuse treatment outcomes in smokers. American Journal on Addictions, 2015; 24(3):252–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25907814

136. Zawertailo LA, Baliunas D, Ivanova A, and Selby PL. Individualized treatment for tobacco dependence in addictions treatment settings: The role of current depressive symptoms on outcomes at 3 and 6 months. Nicotine & Tobacco Research, 2015; 17(8):937–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26180218

137. Winhusen TM, Kropp F, Theobald J, and Lewis DF. Achieving smoking abstinence is associated with decreased cocaine use in cocaine-dependent patients receiving smoking-cessation treatment. Drug and Alcohol Dependence, 2014; 134:391–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24128381

138. Winhusen TM, Brigham GS, Kropp F, Lindblad R, Gardin JG, 2nd, et al. A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. Journal of Clinical Psychiatry, 2014; 75(4):336–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24345356

139. McKelvey K, Thrul J, and Ramo D. Impact of quitting smoking and smoking cessation treatment on substance use outcomes: An updated and narrative review. Addictive Behaviors, 2017; 65:161–70. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27816663

140. Martinez C, Guydish J, Le T, Tajima B, and Passalacqua E. Predictors of quit attempts among smokers enrolled in substance abuse treatment. Addictive Behaviors, 2014; 40C:1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25218064

141. McPherson S, Orr M, Lederhos C, McDonell M, Leickly E, et al. Decreases in smoking during treatment for methamphetamine-use disorders: Preliminary evidence. Behavioural Pharmacology, 2017. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29035917

142. Thurgood SL, McNeill A, Clark-Carter D, and Brose L. A systematic review of smoking cessation interventions for adults in substance abuse treatment or recovery. Nicotine & Tobacco Research, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26069036

143. Khara M and Okoli C. The tobacco-dependence clinic: Intensive tobacco-dependence treatment in an addiction services outpatient setting. American Journal on Addictions, 2010; 20(1):45–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21175920

144. Fucito L, Toll B, Wu R, Romano D, Tek E, et al. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology, 2011; 215(4):655–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21221531  

145. Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, et al. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. Drug and Alcohol Dependence, 2018; 184:12–7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29324248

146. O'Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: A randomized clinical trial. JAMA Psychiatry, 2017. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29261824

147. Hays J, Hurt R, Decker P, Croghan I, Offord K, et al. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. Nicotine & Tobacco Research, 2009; 11(7):859–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19483180

148. Poling J, Rounsaville B, Gonsai K, Severino K, and Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: A pilot study. American Journal on Addictions, 2010; 19(5):401–8. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1521-0391.2010.00066.x/full

149. Yee A, Hoong MC, Joyce YC, and Loh HS. Smoking cessation among methadone-maintained patients: A meta-analysis. Substance Use and Misuse, 2017:1–10. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28857640

150. Drummond MB, Astemborski J, Lambert AA, Goldberg S, Stitzer ML, et al. A randomized study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users. BMC Public Health, 2014; 14:761. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25074396

151. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Sirota AD, et al. Contingent vouchers and motivational interviewing for cigarette smokers in residential substance abuse treatment. Journal of Substance Abuse Treatment, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25805668

152. Cooney JL, Cooper S, Grant C, Sevarino K, Krishnan-Sarin S, et al. A randomized trial of contingency management for smoking cessation during intensive outpatient alcohol treatment. Journal of Substance Abuse Treatment. Available from: http://dx.doi.org/10.1016/j.jsat.2016.07.002

153. Alessi SM, Petry NM, and Urso J. Contingency management promotes smoking reductions in residential substance abuse patients. Journal of Applied Behavior Analysis, 2008; 41(4):617–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19192865

154. Dunn K, Sigmon S, Thomas C, Heil S, and Higgins S. Voucher-based contingent reinforcement of smoking abstinence among methadone-maintained patients: A pilot study. Journal of Applied Behavior Analysis, 2008; 41(4):527–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19192857

155. Dunn K, Sigmon S, Reimann E, Badger G, Heil S, et al. A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients. Experimental and Clinical Psychopharmacology, 2010; 18(1):37–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20158293

156. Alessi SM and Petry NM. Smoking reductions and increased self-efficacy in a randomized controlled trial of smoking abstinence-contingent incentives in residential substance abuse treatment patients. Nicotine & Tobacco Research, 2014; 16(11):1436–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24935755

157. Rohsenow DJ, Tidey JW, Kahler CW, Martin RA, Colby SM, et al. Intolerance for withdrawal discomfort and motivation predict voucher-based smoking treatment outcomes for smokers with substance use disorders. Addictive Behaviors, 2014; 43C:18–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25531536

158. Rohsenow DJ, Martin RA, Monti PM, Colby SM, Day AM, et al. Motivational interviewing versus brief advice for cigarette smokers in residential alcohol treatment. Journal of Substance Abuse Treatment, 2014; 46(3):346–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24210533

159. Finkelstein J, Lapshin O, and Cha E. Feasibility of promoting smoking cessation among methadone users using multimedia computer-assisted education. Journal of Medical Internet Research, 2008; 10(5):e33. Available from: http://www.jmir.org/2008/5/e33/

160. Bowman J and Walsh R. Smoking intervention within alcohol and other drug treatment services: A selective review with suggestions for practical management. Drug and Alcohol Review, 2003; 22(1):73–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12745361

161. Guydish J, Ziedonis D, Tajima B, Seward G, Passalacqua E, et al. Addressing tobacco through organizational change (ATTOC) in residential addiction treatment settings. Drug and Alcohol Dependence, 2012; 121(1–2):30–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21906892  

162. Allsop S, Carter O, and Lenton S. Enhancing clinical research with alcohol, tobacco and cannabis problems and dependence. Drug and Alcohol Review, 2010; 29(5):483–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20887571

163. Fu SS, McFall M, Saxon AJ, Beckham JC, Carmody TP, et al. Post-traumatic stress disorder and smoking: A systematic review. Nicotine & Tobacco Research, 2007; 9(11):1071–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17978982

164. Flanagan JC, Hakes JK, McClure EA, Snead AL, and Back SE. Effects of intimate partner violence, PTSD, and alcohol use on cigarette smoking in a nationally representative sample. American Journal on Addictions, 2016; 25(4):283–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27196699

165. McFall M, Saxon A, Malte C, Chow B, Bailey S, et al. Integrating tobacco cessation into mental health care for posttraumatic stress disorder: A randomized controlled trial. Journal of the American Medical Association, 2010; 304(22):2485–93. Available from: http://jama.ama-assn.org/content/304/22/2485.long

166. McFall M, Saxon AJ, Thompson CE, Yoshimoto D, Malte C, et al. Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. American Journal of Psychiatry, 2005; 162(7):1311–9. Available from: http://dx.doi.org/10.1176/appi.ajp.162.7.1311

167. Barnett PG, Jeffers A, Smith MW, Chow BK, McFall M, et al. Cost-effectiveness of integrating tobacco cessation into post-traumatic stress disorder treatment. Nicotine & Tobacco Research, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25943761

168. Hertzberg MA, Moore SD, Feldman ME, and Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology, 2001; 21(1):94–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11199956/

169. Hertzberg JS, Carpenter VL, Kirby AC, Calhoun PS, Moore SD, et al. Mobile contingency management as an adjunctive smoking cessation treatment for smokers with posttraumatic stress disorder. Nicotine & Tobacco Research, 2013; 15(11):1934–8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790624/

170. Battaglia C, Peterson J, Whitfield E, Min SJ, Benson SL, et al. Integrating motivational interviewing into a home telehealth program for veterans with posttraumatic stress disorder who smoke: A randomized controlled trial. Journal of Clinical Psychology, 2016; 72(3):194-206. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jclp.22252

171. Dedert EA, Resick PA, McFall ME, Dennis PA, Olsen M, et al. Pilot cases of combined cognitive processing therapy and smoking cessation for smokers with posttraumatic stress disorder. Behavior Therapy, 2016; 47(1):54–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26763497

172. Jackson JG, Diaz FJ, Lopez L, and de Leon J. A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults. Bipolar Disorders, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26238269

173. George TP, Wu BS, and Weinberger AH. A review of smoking cessation in bipolar disorder: Implications for future research. Journal of Dual Diagnosis, 2012; 8(2):126–30. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378056/

174. Slyepchenko A, Brunoni AR, McIntyre RS, Quevedo J, and Carvalho AF. The adverse effects of smoking on health outcomes in bipolar disorder: A review and synthesis of biological mechanisms. Curr Mol Med, 2016; 16(2):187–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26812916

175. Thomson D, Berk M, Dodd S, Rapado-Castro M, Quirk SE, et al. Tobacco use in bipolar disorder. Clinical Psychopharmacology and Neuroscience, 2015; 13(1):1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25912533

176. Weinberger A, Vessicchio J, Sacco K, Creeden C, Chengappa K, et al. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. Journal of Clinical Psychopharmacology, 2008; 28(5):584–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18794666

177. Wu BS, Weinberger AH, Mancuso E, Wing VC, Haji-Khamneh B, et al. A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder. Journal of Dual Diagnosis, 2012; 8(2):131–2. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435104/

178. Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: A randomized clinical trial. Journal of the American Medical Association, 2014; 311(2):145–54. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124884/

179. Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, et al. Varenicline for smoking cessation in bipolar disorder: A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 2014; 75(7):765–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25006684

180. McGrath JJ and Sasser ES. New directions in the epidemiology of schizophrenia. Medical Journal of Australia, 2009; 190(4):S7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19220176

181. Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, et al. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. Journal of Psychiatric Research, 2014; 48(1):102–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24139811

182. Williams JM and Foulds J. Successful tobacco dependence treatment in schizophrenia. American Journal of Psychiatry, 2007; 164(2):222–7; quiz 373. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17267783

183. Kelly DL, Raley HG, Lo S, Wright K, Liu F, et al. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophrenia Bulletin, 2012; 38(3):543–51. Available from: http://schizophreniabulletin.oxfordjournals.org/content/38/3/543.abstract

184. Williams JM and Ziedonis DM. Snuffing out tobacco dependence. Behavioral Healthcare, 2006; 26(5):27–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16736916

185. Tsoi DT, Porwal M, and Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews, 2013; 2:Cd007253. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23450574

186. Baker A, Richmond R, Lewin T, and Kay-Lambkin F. Cigarette smoking and psychosis: Naturalistic follow up 4 years after an intervention trial. The Australian and New Zealand Journal of Psychiatry, 2010; 44(4):342–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20307166

187. Miyauchi M, Kishida I, Suda A, Shiraishi Y, Fujibayashi M, et al. Long term effects of smoking cessation in hospitalized schizophrenia patients. BMC Psychiatry, 2017; 17(1):87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28270120

188. Kishi T and Iwata N. Varenicline for smoking cessation in people with schizophrenia: Systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 2015; 265(3):259–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25283510

189. Stubbs B, Vancampfort D, Bobes J, De Hert M, and Mitchell AJ. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatrica Scandinavica, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25754402

190. Evins AE and Cather C. Effective cessation strategies for smokers with schizophrenia. Int Rev Neurobiol, 2015; 124:133–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26472528

191. US Food and Drug Administration (FDA). Joint meeting of the psychopharmacologic drugs advisory committee and drug safety and risk management advisory committee. 2016. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM520103.pdf

192. Jeon DW, Shim JC, Kong BG, Moon JJ, Seo YS, et al. Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: A randomized double-blind placebo-controlled trial. Schizophrenia Research, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27543252

193. Smith RC, Amiaz R, Si TM, Maayan L, Jin H, et al. Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: A double-blind randomized trial. PLoS ONE, 2016; 11(1):e0143490. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26730716

194. Wu Q, Gilbody S, Peckham E, Brabyn S, and Parrott S. Varenicline for smoking cessation and reduction in people with severe mental illnesses: Systematic review and meta-analysis. Addiction, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27043328

195. Cather C, Pachas GN, Cieslak KM, and Evins AE. Achieving smoking cessation in individuals with schizophrenia: Special considerations. CNS Drugs, 2017; 31(6):471–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28550660

196. [No authors listed]. For the patient. Do African American teens have equal access to nicotine patch and gum? Ethnicity & Disease, 2010; 20(2):195. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20503903

197. The crisis in correctional health care: The impact of the national drug control strategy on correctional health services. American college of physicians, national commission on correctional health care, and American correctional health services association. Annals of Internal Medicine, 1992; 117(1):71–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1596049

198. Skelton E, Tzelepis F, Shakeshaft A, Guillaumier A, Dunlop A, et al. Smoking cessation care provision in Australian alcohol and other drug treatment services: A cross-sectional survey of staff self-reported practices. Journal of Substance Abuse Treatment, 2017; 77:101–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28476261

199. Sharma R, Meurk C, Bell S, Ford P, and Gartner C. Australian mental health care practitioners' practices and attitudes for encouraging smoking cessation and tobacco harm reduction in smokers with severe mental illness. International Journal of Mental Health Nursing, 2017. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28160384

200. Abrantes A, Strong D, Lloyd-Richardson E, Niaura R, Kahler C, et al. Regular exercise as a protective factor in relapse following smoking cessation treatment. American Journal on Addictions, 2009; 18(1):100–1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19219672

201. Ratschen E, Britton J, Doody GA, Leonardi-Bee J, and McNeill A. Tobacco dependence, treatment and smoke-free policies: A survey of mental health professionals' knowledge and attitudes. General Hospital Psychiatry, 2009; 31(6):576–82. Available from: http://www.sciencedirect.com/science/journal/01638343

202. Skelton E, Tzelepis F, Shakeshaft A, Guillaumier A, Dunlop A, et al. Addressing tobacco in Australian alcohol and other drug treatment settings: A cross-sectional survey of staff attitudes and perceived barriers. Substance Abuse Treatment, Prevention, and Policy, 2017; 12(1):20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28464898

203. Wye P, Bowman J, Wiggers J, Baker A, Carr V, et al. Providing nicotine dependence treatment to psychiatric inpatients: The views of Australian nurse managers. Journal of Psychiatric and Mental Health Nursing, 2010; 17(4):319–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20529182

204. Knudsen HK. Implementation of smoking cessation treatment in substance use disorder treatment settings: A review. American Journal of Drug and Alcohol Abuse, 2016:1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27314884

205. Pagano A, Tajima B, and Guydish J. Barriers and facilitators to tobacco cessation in a nationwide sample of addiction treatment programs. Journal of Substance Abuse Treatment, 2016; 67:22–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27296658

206. Sheals K, Tombor I, McNeill A, and Shahab L. A mixed-method systematic review and meta-analysis of mental health professionals' attitudes toward smoking and smoking cessation amongst people with mental illnesses. Addiction, 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27003925

207. Johnson J, Malchy L, Ratner P, Hossain S, Procyshyn R, et al. Community mental healthcare providers' attitudes and practices related to smoking cessation interventions for people living with severe mental illness. Patient Education and Counseling, 2009; 77(2):289–95. Available from: http://www.pec-journal.com/article/PIIS0738399109000858/fulltext

208. Schwindt RG, McNelis AM, and Sharp D. Evaluation of a theory-based education program to motivate nursing students to intervene with their seriously mentally ill clients who use tobacco. Archives of Psychiatric Nursing, 2014; 28(4):277–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25017562

209. Williams JM, Stroup TS, Brunette MF, and Raney LE. Integrated care: Tobacco use and mental illness: A wake-up call for psychiatrists. Psychiatric Services, 2014. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25270381

210. Cerimele JM, Halperin AC, and Saxon AJ. Tobacco use treatment in primary care patients with psychiatric illness. Journal of the American Board of Family Medicine, 2014; 27(3):399–410. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24808119

211. Mitchell AJ, Vancampfort D, De Hert M, and Stubbs B. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis. General Hospital Psychiatry, 2015; 37(1):14–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25510845

212. Shi Y. Smoking cessation among people seeking mental health treatment. Psychiatric Services, 2014; 65(7):957–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26037007

213. Rogers E and Sherman S. Tobacco use screening and treatment by outpatient psychiatrists before and after release of the American psychiatric association treatment guidelines for nicotine dependence. American Journal of Public Health, 2014; 104(1):90–5. Available from: 

http://www.ncbi.nlm.nih.gov/pubmed/24228666

 

214. [No authors listed]. An official position statement of the association of women’s health, obstetric & neonatal nursing. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2010; 39(5):611–3. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1552-6909.2010.01178.x/full

215. Quit Victoria. Mental health settings. 2016. Available from: http://www.quit.org.au/resource-centre/communities/mental-health-settings

216. Adams C, Baillie L, and Copeland A. The smoking-related weight and eating episodes test (sweet): Development and preliminary validation. Nicotine & Tobacco Research, 2011; 13(11):1123–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21849410 

217. Ashton M. Policy within mental health services: Pro-actively addressing tobacco. The Mental Health Service Conference, 2005. 

218. Wye P, Bowman J, Wiggers J, Baker A, Carr V, et al. An audit of the prevalence of recorded nicotine dependence treatment in an Australian psychiatric hospital. Australian and New Zealand Journal of Public Health, 2010; 34(3):298–303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20618273

219. Wye P, Bowman J, Wiggers J, Baker A, Knight J, et al. Smoking restrictions and treatment for smoking: Policies and procedures in psychiatric inpatient units in Australia  Psychiatric Services (Washington, D.C.), 2009; 60(1):100–7. Available from: http://ps.psychiatryonline.org/cgi/content/full/60/1/100

220. Abrams D, Graham A, Levy D, Mabry P, and Orleans C. Boosting population quits through evidence-based cessation treatment and policy. American Journal of Preventive Medicine, 2010; 38(3 suppl.):S351–63. Available from: http://www.ajpm-online.net/article/PIIS0749379709008939/fulltext

221. Shmueli D, Fletcher L, Hall S, Hall S, and Prochaska J. Changes in psychiatric patients' thoughts about quitting smoking during a smoke-free hospitalization. Nicotine & Tobacco Research, 2008; 10(5):875–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18569762

222. Keizer I, Descloux V, and Eytan A. Variations in smoking after admission to psychiatric inpatient units and impact of a partial smoking ban on smoking and on smoking-related perceptions. International Journal of Social Psychiatry, 2009; 55(2):109–23. Available from: http://isp.sagepub.com/cgi/reprint/55/2/109

223. Stockings EA, Bowman JA, Prochaska JJ, Baker AL, Clancy R, et al. The impact of a smoke-free psychiatric hospitalization on patient smoking outcomes: A systematic review. Australian and New Zealand Journal of Psychiatry, 2014; 48(7):617–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24819934

224. Leyro TM, Hall SM, Hickman N, Kim R, Hall SE, et al. Clinical management of tobacco dependence in inpatient psychiatry: Provider practices and patient utilization. Psychiatric Services, 2013; 64(11):1161–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24185538

225. Prochaska JJ, Fletcher L, Hall SE, and Hall SM. Return to smoking following a smoke-free psychiatric hospitalization. American Journal on Addictions, 2006; 15(1):15–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16449089

226. Vorspan F, Bloch V, Guillem E, Dupuy G, Pirnay S, et al. Smoking ban in a psychiatry department: Are nonsmoking employees less exposed to environmental tobacco smoke? European Psychiatry, 2009; 24(8):529–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19540729

227. Stockings EA, Bowman JA, Bartlem KM, McElwaine KM, Baker AL, et al. Implementation of a smoke-free policy in an inpatient psychiatric facility: Patient-reported adherence, support, and receipt of nicotine-dependence treatment. International Journal of Mental Health Nursing, 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25970237

228. Filia SL, Gurvich CT, Horvat A, Shelton CL, Katona LJ, et al. Inpatient views and experiences before and after implementing a totally smoke-free policy in the acute psychiatry hospital setting. International Journal of Mental Health Nursing, 2015; 24(4):350–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26189488

229. Magor-Blatch LE and Rugendyke AR. Going smoke-free: Attitudes of mental health professionals to policy change. Journal of Psychiatric and Mental Health Nursing, 2016; 23(5):290–302. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27278902

230. Oliveira RM and Furegato AR. The decreasing number of cigarettes during psychiatric hospitalization: Intervention or punishment? Revista Brasileira de Enfermagem, 2015; 68(1):76–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25946498

231. Chapman S. A complete smoking ban in psychiatric hospitals is ethically wrong. British Medical Journal, 2015; 351:h6288. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26607749

232. Arnott D, Wessely S, and Fitzpatrick M. Should psychiatric hospitals completely ban smoking? British Medical Journal, 2015; 351:h5654. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26536887